Pharmaceutical composition for anti-angiogenesis containing cyclic pentadepsipeptide as an effective ingredient

Patent metadata

Field	Value
Publication number	US-10709757-B2
Application number	US-201816320502-A
Country	US
Kind code	B2
Filing date	Feb 6, 2018
Priority date	Feb 9, 2017
Publication date	Jul 14, 2020
Grant date	Jul 14, 2020

Abstract

The present invention relates to a composition for inhibiting angiogenesis, containing neo-N-methylsansalvamide (NMSSV), which is a cyclic pentadepsipeptide, as an effective ingredient, and specifically, since the NMSSV of the present invention has excellent activity which inhibits cell migration and tube formation associated with angiogenesis, and concentration-dependently inhibits angiogenesis induced by a vascular endothelial growth factor, it is expected that the NMSSV of the present invention may inhibit angiogenesis and be usefully used as a therapeutic agent for various diseases in which angiogenesis is abnormally regulated.

First claim

The invention claimed is:

1. A method for inhibiting angiogenesis, wherein the method comprises administering a pharmaceutical composition for inhibiting angiogenesis, comprising an isolated cyclic pentadepsipeptide of the following Chemical Formula 1 as an effective ingredient, to a subject in need thereof,

wherein the peptadepsipeptide inhibits the proliferation of vascular endothelial cells.

2. The method of claim 1 , wherein the composition is capable of preventing or treating an angiogenesis-related disease.

3. The method of claim 2 , wherein the disease is any one disease selected from a group consisting of arthritis, rheumatoid arthritis, chronic inflammation, osteoarthritis, diabetic retinopathy, retinopathy of prematurity, neovascular glaucoma, a corneal disease caused by neovascularization, macular degeneration, spot degeneration, pterygium, retinal degeneration, erythrosis, proliferative retinopathy, retrolental fibroplasia, granular conjunctivitis, capillarectasia, granuloma pyogenicum, psoriasis, seborrheic dermatitis, and acne.

4. The method of claim 1 , wherein the isolated cyclic pentadepsipeptide of Chemical Formula 1 inhibits the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), protein kinase B (AKT) or endothelial nitric oxide synthase (eNOS) in vascular endothelial cells.

5. The method of claim 1 , wherein the isolated cyclic pentadepsipeptide of Chemical Formula 1 inhibits the cell migration of vascular endothelial cells.

6. The method of claim 1 , wherein the isolated cyclic pentadepsipeptide of Chemical Formula 1 inhibits tube formation by differentiation of vascular endothelial cells.

7. A method for treating an angiogenesis-related disease, the method comprising administering a cyclic pentadepsipeptide of the following chemical formula 1 to a subject in need thereof,

wherein the angiogenesis-related disease is any one disease selected from a group consisting of arthritis, rheumatoid arthritis, chronic inflammation, osteoarthritis, diabetic retinopathy, retinopathy of prematurity, neovascular glaucoma, a corneal disease caused by neovascularization, macular degeneration, spot degeneration, pterygium, retinal degeneration, erythrosis, proliferative retinopathy, retrolental fibroplasia, granular conjunctivitis, capillarectasia, granuloma pyogenicum, psoriasis, seborrheic dermatitis, and acne.

Assignees

• Univ Chung Ang Ind Acad Coop Found

Inventors

• Lee Chan
• Moon Sung-Kwon
• Kim Jee Taek

Classifications

• A61K38/15 Primary

  Depsipeptides; Derivatives thereof · CPC title

• A61P27/02

  Ophthalmic agents · CPC title